Bioflorin – Enterococcus faecium SF 68

This is the latest discovery of an unusual probiotic, it is used for acute adult diarrhea. Availability is in Germany (unfortunately Amazon.de does not carry it). On line German pharmacies do,  for example at this site.

What do we know about it? There are 13 PubMed articles:

  • “Probiotic enterococci a widely used by pediatricians and infection diseases doctors in Russia as means for the treatment of dysbiosis, irritated bowel syndrome and in the treatment and prevention of different functional and chronic intestinal diseases. Strains E. faecium M74 and E. faecium SF-68 are included in several probiotic drugs and have been proved as effective and safe.” [2013]
  • “Enterococcus faecium SF 68 (sensitive to penicillin, tetracycline, virginiamicin and tylosin, but resistant to streptomycin)” [1994]
  • “An antagonistic activity of Enterococcus faecium SF 68 towards Plesiomonas shigelloides, Aeromonas sp., enteropathogenic Escherichia coli and Yersinia enterocolitica has been studied and demonstrated.’ [1990]
  • Efficacy of SF 68 in the treatment of acute diarrhea. A placebo-controlled trial.[1996]

  • “All treatments were continued for 7 days. Enterococcus SF 68 was shown to be effective in reducing the incidence of antibiotic-associated diarrhoea in comparison with placebo (8.7% compared with 27.2%, respectively). Patients with acute enteritis showed a significantly faster resolution of bowel abnormalities during treatment with Enterococcus SF68 compared with placebo.” [1989]

NOTE: It appears to be available in the US as a probiotic for dogs — “FORTIFLORA® CANINE NUTRITIONAL SUPPLEMENT”

 

Miyarisan (Clostridium butyricum) – Revisited

When I last looked at Miyarisan, it was available in Japan only. In the last month I discovered that it is now available in the US and EU — thus it is a good time to revisit it.

2020 Update

One of the characteristics that is connected with a lot of the stuff that my model suggests, is that they are often used for diarrhea and other digestive discomfort. In other words, been show effective against common disruptive bugs in the gut. Mutaflor (E.Coli Nissle 1917) and Miyarisan are both traditionally used for that — not as regular daily probiotics, but as probiotics when symptoms require the gut to be fixed. The interesting aspect is this:

  • Mutaflor — the only E.Coli probiotic (and many E.Coli are nasty)
  • Clostridium butyricum – the only Clostridium probiotic that I am aware of (and many Clostridium are Difficult (i.e. difficile))
4115XV4D8TL

Clostridium butyricum MIYAIRI 588® (CBM 588®), an anaerobic spore-forming bacterium, has been developed as a probiotic for use by humans and food animals.

Do NOT take with E.Coli Probiotics

“1.1 C. butyricum MIYAIRI antagonistic effects on toxinogenic Escherichia coli and 20 E. coli strains isolated from live stocks (cows, pigs and chickens) were evaluated by the plating method. C. butyricum MIYAIRI inhibited the growth of all E. coli strains tested” [Source]

Anxiety

  • “Reduced anxiety levels from 19.8 to 10.2 in the HAMA Attenuated the increase in CRF and HR pre op” [2015] [2014]

Histamines

This probiotic produces butyric acid (BTA) which is a histamine antagonist [source].

“An important mechanism by which butyrate causes biological effects in colon carcinoma cells is the hyperacetylation of histones by inhibiting histone deacetylase” [2011]

“In humans, the effects of BA can be subdivided into intestinal and extra-intestinal. Intestinal effects include: regulating transepithelial transport, improving the inflammatory and oxidative states of the intestinal mucosa, reinforcing the mucosal barrier, modulating visceral sensitivity and motility, and preventing and inhibiting colon carcinoma. Extraintestinal effects are less well known; they have been studied in vitro and in animal models and sometimes even in humans. Currently investigated effects include: haemoglobinopathies, hypercholesterolaemia, reducing resistance to insulin (in animal studies), and reducing ischemic stroke (in animal studies).” [2012][2011]

Butyrate Studies with IBS

Butyrate is produced by Miyarisan.

“Butyrates represent a potential new IBS therapy. To date, a few trials have been performed to evaluate the effectiveness of sodium butyrate on clinical symptoms and quality of life in patients with IBS. Banasiewicz et al. performed a double-blind, randomized, placebo-controlled study in which 66 adult patients with IBS received microcapsulated butyric acid at a dose of 300 mg per day or placebo as an adjunct to standard therapy. At four weeks, there was a statistically significant decrease in the frequency of abdominal pain during defecation in the butyric acid group (p = 0.0032). At 12 weeks, decreases in the frequency of spontaneous abdominal pain (p = 0.0132), postprandial abdominal pain (p = 0.0031), abdominal pain during defecation (p = 0.0002) and urge after defecation (p = 0.0100) were observed [9, 10]. In a preliminary report, Tarnowski et al. demonstrated an improvement of abdominal pain, abdominal discomfort and defecation rhythm in patients with IBS treated with microcapsulated sodium butyrate for 6 weeks, compared to those treated with placebo. In the same study, higher quality of life was noted in patients treated with butyrate [11].” [2013]

Addendum on Brain Injury

Personal Observations

Both my wife and I found we slept hard when we started taking this. By hard, I mean sleeping thru four(4) alarm clocks. For myself, I woke with less adrenalin than usual, more relaxed. As usual, your experience may be different due to different microbiome.

Probiotics available in the EU and UK

A reader asked me about what probiotics are available in the UK or EU that are suitable. I will largely be using Amazon sites because of greatest variety and ease of use — especially for home bound CFSers

WARNING: Some of these require refrigeration and shipping with ice-packs. Marked with ***. Verify from seller before ordering.

If you know of others, please comment on this page.

CFS as Post-infectious Disease Syndrome

My model of CFS is that is the result of a stable dysfunction in microbiome after an illness or other event (which can include inoculations, stress, etc). The short answer is that the microbiome change caused by the illness stayed, and with it, many of the symptoms of the illness. This implies that many symptoms are the result of the microbiome changes and NOT directly connected to the infection.

I thought a quick review of the literature on PIDS would be informative. A good summary from 1988, is a smart place to start.

“Many post-infectious syndromes have been recognized in the last 50 years [from 1938!], some following viral infections and others closely related to bacterial disease. The occurrence of prolonged fatigue following an apparent viral illness of varying severity is also well documented. The lack of a recognizable precipitating cause and the tendency for epidemic fatigue to occur among hospital staff led many to believe that the illness may be psychogenic in origin.” It cites mononucleosis (Epstein-Barr virus) and enterovirus“

A related article entitled Post-Infectious Fatigue was published in 1987, which writes

“In most cases the illness is attributed to a chronic Epstein-Barr virus infection. Symptoms include weakness and fatigue in the absence of physical findings or significant laboratory abnormalities. These patients are frequently depressed and have considerable disability resulting in prolonged loss of time from work. The illness may be persistent or can be relapsing, but often lingers for two years or more. There is no effective therapy.”

Jumping ahead to 1998, we find “Post-infection fatigue syndrome following Q fever“,

“In summary, we conclude that a syndrome characterized by undue fatigue, breathlessness on exertion, excessive sweating and blurring of vision occurs after infection by Coxiella burnetii, and that these symptoms persist for many years. The mechanism for this effect remains elusive, but possibilities such as sub-clinical cardiomyopathy or autonomic dysfunction need to be tested using this unique cohort of patients.”

Post-infectious irritable bowel syndrome (PI-IBS) may develop in 4 – 31 % of affected patients following bacterial gastroenteritis (GE), symptoms persist after successful treatment in some for months as shown below taken from this 2005 article. Note that at 1 year, there are some still showing symptoms.

Screen Shot 2015-10-17 at 3.51.18 PM

In 2014, a followup study was done on some 1252 patients that had a Giardia Infection and were successfully treated. They found:

  • irritable bowel syndrome (39.4%) by Rome III criteria – Relative risk to matched population 3.4 times as likely
  • chronic fatigue (30.8%) in the exposed group – Relative risk to matched population 2.9 times as likely

As time went on from 3 years to 6 years:

  • the prevalence of irritable bowel syndrome decreased by 6.7%
  • the prevalence of chronic fatigue decreased by 15.3%

“Development of IBS in a subset of patients with acute gastroenteritis is uncontested. This is expected to open a paradigm shift in understanding the pathogenesis of IBS.” [2011]

Summary

The mechanism for Post-Infection Fatigue has traditionally been not understood by the medical establishment. There is growing evidence that it is a slow (or never) return from a shifted microbiome caused by a disease, vaccination, antibiotic, stress, etc (and I mean and so forth — the list goes on and on) that may be the cause.

“A growing body of work provides evidence supporting a role for pathogen-mediated modifications in the resident intestinal microbiota, epithelial barrier integrity, effector cell functions, and innate and adaptive immune features, all proposed physiological manifestations that can underlie GI abnormalities in IBS.” [2014]

Or as this title states, Redefining the gut as the motor of critical illness.

Review on news about Probiotics

This is a periodic review of news stories dealing with probiotics — all aspects — that happened in the last few months:

  • Why one probiotic strain may be a drug (FDA regulated and requiring a prescription) and another in the same family is a unregulated supplement [explanation]
  • “our results suggest that high altitude may contribute to shaping human gut microbiota.”[2015]
  • “the decreased relative abundance of the Mucor genus in obese subjects was reversible upon weight loss. Collectively, these findings suggest that manipulation of gut mycobiome communities might be a novel target in the treatment of obesity.” [Nature]
  • “In 2000, a flood in the Canadian town of Walkerton contaminated the town’s drinking water with pathogens such as Escherichia coli and Campylobacter jejuni. About 2,300 people suffered from severe gastrointestinal infection, and many of them developed chronic irritable bowel syndrome (IBS) as a direct result.During an eight-year study1 of Walkerton residents, led by gastroenterologist Stephen Collins at McMaster University in Hamilton, Canada, researchers noticed that psychological issues such as depression and anxiety seemed to be a risk factor for persistent IBS.” [Nature]
  • Yakult has joined fellow probiotic giant Danone in winning health claims for its probiotic yoghurt drinks in Switzerland.http://www.dairyreporter.com/Regulation-Safety/Yakult-wins-Swiss-probiotic-health-claim, namely “Yakult contributes to the normal functioning of the intestine by improving stool consistency and reducing transit time”

  • “contrasting effects of the same spice (turmeric), illustrate the importance of understanding the interaction between diet, microbes and specific functions of members of the human gut microbiota…The researchers also found that returning to the home diet at the end of the simulated journey[of diet from elsewhere in the world] did not restore transit times to their pre-travel baselines, suggesting long-term effects of temporary diet changes.” [2015]
  • “individuals could be uniquely identified by the combination of bacteria in the air surrounding them.” [The Scientist]
  • “Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome:“
  • Ibsium (strain of Saccharomyces cerevisiae) claim that “helps to reduce abdominal pain and discomfort associated with IBS” has been a been approved by Canada (i.e. sufficient studies to support claim) [2015]
  • certain probiotic strains (bacteroides thetaiotaomicron, Faecalibacterium prausnitzii, Streptococcus thermophilus) may increase iron uptake and storage [2015]
  • “this study goes farther to show that feeding different types of fat result in very different composition of gut microbiota,” [The Scientist]
  • Keeping Gut Bacteria in Balance Could Help Delay Age-related Diseases

  • “New research enables “tailored” diet advice – based on our personal gut microbiome – for persons who want to lose weight and reduce the risk of disease. Systems biologists at Chalmers University of Technology have for the first time successfully identified in detail how some of our most common intestinal bacteria interact during metabolism.The researchers at Chalmers University of Technology have developed a mathematical calculation platform that makes it possible to predict how different patients will respond to a modified diet, depending on how their gut microbiome is composed.[2015] [2015]

  • “We used a variety of antibiotic perturbations to generate a diverse array of gut microbiota structures, which were then challenged with C. difficile spores. Across these treatments we observed that C. difficile resistance was never attributable to a single organism, but rather it was the result of multiple microbiota members interacting in a context-dependent manner… Together, these results indicate that individual bacterial populations do not drive colonization resistance to C. difficile. Rather, multiple diverse assemblages act in concert to mediate colonization resistance [ASM]

  • Consumption of Lactobacillus reuteri probiotics may boost insulin release in healthy people, says a new study [2015]

  • Researchers identify signature of microbiomes associated with schizophrenia[2015]

  • T cells activated in the microbe-dense gut can spark an autoimmune eye disease, [The Scientist]

  • The normal smell of human faeces is largely due to indole, one of the major metabolites. Recent studies indicate that this foul-smelling substance is also of utmost importance for our health. Today, it is considered possible that alterations of the microbiome (‘dysbiosis’) may be a major cause not only of irritable bowel syndrome, fibromyalgia, and chronic fatigue syndrome but also a number of other common diseases such as obesity, diabetes mellitus, atherosclerosis, and allergic and autoimmune diseases (3, 4). Indole is an example of a microbe-generated signal substance that has positive effects on its host as well as the microbiome, and normal-smelling faeces may be an underestimated health indicator. [2015]

  • Fifteen of the products tested during the study, presented during Digestive Disease Week (DDW) in Washington, D.C., May 17to19, were labeled gluten-free. Of those labeled gluten-free, six contained gluten in amounts permissible by FDA. [2015]

  • The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment [Nature]

  • Microbial cocktails join fecal transplants in IBD treatment trials [Nature] The cocktail contains some 50 species. [Company]

  • show how bacterial biofilms found in the gut can provoke the onset of lupus in lupus-prone mice [NeuroScientistNews]

  • A high-fat diet may affect the bacterial populations in the gut and detrimentally affect satiety signaling to the brain, says a new study using lab rats [2015]

  • The probiotic Lactobacillus rhamnosus GG ATCC 53103 may not change the host’s gut microbiota but may stimulate anti-inflammatory activities of microbes already resident, says a new study [2015]